EU/3/14/1414

About

On 15 January 2015, orphan designation (EU/3/14/1414) was granted by the European Commission to Hope Pharmaceuticals, Ltd, United Kingdom, for sodium thiosulfate for the treatment of calciphylaxis.

The sponsor’s address was updated in March 2019.

Key facts

Active substance
Sodium thiosulfate
Disease / condition
Treatment for calciphylaxis
Date of first decision
15/01/2015
Outcome
Positive
EU designation number
EU/3/14/1414

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Hope Pharmaceuticals, Ltd
3rd Floor
124 Baker Street
London W1U 6TY
United Kingdom
Tel. +44 (0)20 3318 8112
E-mail: questions@hopepharm.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating